US5697967A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug eluting stent
Assignee: Medtronic Inc
•
Filing: 1995-04-27
•
Granted: 1997-12-16
•
Expires: 2015-04-27
Abstract
Abstract An intraluminal stent comprising fibrin and an elutable drug is capable of providing a treatment of restenosis.
Inventors
- 👤 Thomas Q. Dinh
- 👤 Ronald J. Tuch
- 👤 Robert S. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:52
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61L; A61L31/00; A61L31/04; A61L31/041; A61L31/043; A61L31/046; A61L31/047; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61L31/128; A61L31/14; A61L31/16; A61F2/0077; A61F2240/00; A61F2240/001; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2420/00; A61L2420/08; B; B05; B05C; B05C3/00; B05C3/20; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
76 words
A method for delivery of a therapeutic substance to the interior of a body lumen comprising the steps of: (a) providing a generally cylindrical stent body; (b) applying to the stent body a first layer which is a solid composite of polymer and therapeutic substance; (c) applying fibrin over the composite; (d) introducing the stent transluminally into a selected portion of the body lumen; and (e) radially expanding the stent into contact with the body lumen.
Claim 2
Independent Claim
76 words
A method for delivery of a therapeutic substance to the interior of a body lumen comprising the steps of: (a) providing a generally cylindrical stent body; (b) applying to the stent body a first layer which is a solid composite of polymer and therapeutic substance; (c) applying fibrin over the composite; (d) introducing the stent transluminally into a selected portion of the body lumen; and (e) radially expanding the stent into contact with the body lumen.
Claim 3
Dependent Claim
55 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes a solvent, a polymer dissolved in the solvent and a therapeutic substance dispersed in the solvent; and (b) evaporating the solvent to form a composite of polymer and therapeutic substance.
Claim 4
Dependent Claim
12 words
The method of claim 2 wherein the solution is applied by spraying.
Claim 5
Dependent Claim
18 words
The method of claim 2 wherein the solution is applied in a plurality of application and drying steps.
Claim 6
Dependent Claim
27 words
The method of claim 2 wherein a ratio of therapeutic substance to dissolved polymer in the solution is varied in some of the plurality of application steps.
Claim 7
Dependent Claim
12 words
The method of claim 2 wherein the polymer is a bioabsorbable polymer.
Claim 8
Dependent Claim
20 words
The method of claim 6 wherein the polymer is selected from the group consisting of poly(L-lactic acid), poly(lactide-co-glycolide) and poly(hydroxybutyrate-co-valerate).
Claim 9
Dependent Claim
12 words
The method of claim 2 wherein the polymer is a biostable polymer.
Claim 10
Dependent Claim
29 words
The method of claim 8 wherein the polymer is selected from the group consisting of silicones, polyurethanes, polyesters, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers and cellulosics.
Claim 11
Dependent Claim
56 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes fibrinogen; (b) applying thrombin to the fibrinogen on the stent body to effect polymerization of the fibrinogen; and (c) applying a therapeutic substance to the fibrinogen as the fibrinogen is polymerizing.
Claim 12
Dependent Claim
48 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes fibrinogen and a dispersed therapeutic substance; and (b) applying thrombin to the fibrinogen on the stent body to effect polymerization of the fibrinogen.
Claim 13
Dependent Claim
39 words
The method of claim 1 wherein the therapeutic substance is selected from the group consisting of glucocorticoids, heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents.
Claim 14
Dependent Claim
22 words
The method of claim 1 wherein the fibrin is applied by molding a polymerization mixture of fibrinogen and thrombin onto the composite.
Claim 15
Independent Claim
83 words
A method for delivery of a therapeutic substance to an interior of a body lumen comprising the steps of: (a) providing a generally cylindrical stent having a body, said body having applied thereto a first layer which is a solid composite of polymer and therapeutic substance and a layer of fibrin as a second layer over the composite; (b) introducing the stent transluminally into a selected portion of the body lumen; and (c) radially expanding the stent into contact with the body lumen.
Claim 16
Independent Claim
83 words
A method for delivery of a therapeutic substance to an interior of a body lumen comprising the steps of: (a) providing a generally cylindrical stent having a body, said body having applied thereto a first layer which is a solid composite of polymer and therapeutic substance and a layer of fibrin as a second layer over the composite; (b) introducing the stent transluminally into a selected portion of the body lumen; and (c) radially expanding the stent into contact with the body lumen.
Claim 17
Dependent Claim
12 words
The method of claim 14 wherein the polymer is a bioabsorbable polymer.
Claim 18
Dependent Claim
20 words
The method of claim 15 wherein the polymer is selected from the group consisting of poly(L-lactic acid), poly(lactide-co-glycolide) and poly(hydroxybutyrate-co-valerate).
Claim 19
Dependent Claim
12 words
The method of claim 14 wherein the polymer is a biostable polymer.
Claim 20
Dependent Claim
29 words
The method of claim 17 wherein the polymer is selected from the group consisting of silicones, polyurethanes, polyesters, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers and cellulosics.
Claim 21
Dependent Claim
39 words
The method of claim 14 wherein the therapeutic substance is selected from the group consisting of glucocorticoids, heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents.
References Cited (Backward Citations)
US3523807A
Cited
US4622244A
Cited
US4464317A
Cited
US4389330A
Cited
US4675189A
Cited
US4530840A
Cited
US4542025A
Cited
US4540573A
Cited
US4548736A
Cited
US5223420A
Cited
US4642242A
Cited
US4600652A
Cited
US5116962A
Cited
US4720512A
Cited
US4943449A
Cited
US5061276A
Cited
US4897268A
Cited
US4886062A
Cited
EP0364787B1
Cited
EP0366564A2
Cited
WO1990013332A1
Cited
US5141516A
Cited
WO1991012779A1
Cited
US5092841A
Cited
US5246451A
Cited
WO1992022312A1
Cited
US5272074A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-15 | 2001-06-16 | 2001-12-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-15 | 2005-06-16 | 2005-12-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-15 | 2009-06-16 | 2009-12-16 | $7700.00 | Window Closed / Lapsed |